Drug Profile
Research programme: axon regeneration therapeutics - Advirna/BioAxone BioSciences
Alternative Names: BA 277Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Advirna; BioAxone Biosciences
- Developer BioAxone Biosciences
- Class Small interfering RNA
- Mechanism of Action Chondroitin sulfate proteoglycan inhibitors; PTEN inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Spinal cord injuries
Most Recent Events
- 22 Aug 2023 Preclinical development in Spinal-cord-injuries is ongoing
- 28 Nov 2020 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA
- 19 Nov 2018 RXi Pharmaceuticals is now called Phio Pharmaceuticals